Bio­phar­ma stocks take a beat­ing as eco­nom­ic tur­moil takes its toll — but some play­ers with coro­n­avirus ef­forts un­der­way are up

The Bio­gen coro­n­avirus out­break has left most of its staff work­ing from home — and it’s been no help for its share price. The stock $BI­IB is down $5.5% Mon­day morn­ing, as bio­phar­ma in gen­er­al takes a beat­ing dur­ing a stretch of se­vere eco­nom­ic tur­moil.

As of this morn­ing Sau­di Ara­bia has de­clared an all-out price war with Rus­sia over oil prices, which is dri­ving down fu­tures and roil­ing the stock mar­ket even fur­ther as the US and Eu­rope looks at the im­pact of a swoon­ing econ­o­my try­ing to shed the im­pact of a pan­dem­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.